In Brief: Investigators ID Novel Plasma Proteins Linked to Future Risk of Hypertension

Written by: Jacqueline Mitchell Media contact: Katherine.Brace@bilh.org

JULY 02, 2024

Exercise testing can serve as a powerful physiologic probe to unmask subclinical cardiovascular abnormalities well before disease onset. For example, blood pressure changes during exercise (EBP) can reveal a latent tendency toward future development of hypertension. At present, there is no reliable circulating biomarker—a protein or other molecule present in the blood stream—indicative of hypertension risk.

Investigators at Beth Israel Deaconess Medical Center (BIDMC) identified unique circulating proteins that reflect EBP and that may, in turn, be early indicators of future risk of hypertension. Led by Robert E. Gerszten, MD, director of BIDMC’s nationally recognized Program in Personal Genomics and Cardiometabolic Disease, Jeremy Robbins, MD, and Mark Sarzynski, PhD, the scientists performed large-scale proteomic profiling and EBP measurements among 681 healthy adults who underwent cardiopulmonary exercise testing before and after 20 weeks of endurance exercise training.

The study team, including lead author Prashant Rao, MBBS, identified 37 proteins associated with EBP, many of which would not have been identified through profiling resting BP alone. Several of these proteins were relevant to vascular biology.

The investigators demonstrated that the EBP-associated plasma protein known as TGFBR3 is a novel circulating biomarker associated with a lower risk of incident hypertension. Genetically predicted levels of this plasma protein were inversely associated with future hypertension risk in a diverse population and may protect against the development of CVD. This work may help in determining which patients might benefit from early clinical interventions to reduce the impact of cardiovascular disease.

Read the full paper in JAMA Cardiology

BIDMC Study Authors: Jeremy Robbins, MD, Robert Gerszten, MD, Prashant Rao, MD, Michelle. J. Keyes, Michael Y. Mi, Jacob L. Barber, Usman A. Tahir, Shuliang Deng, Dongxiao Shen, Laurie. A. Farrell, James G. Wilson

COI: No disclosures were reported.

Citation: Rao, P (2024) “Plasma Proteomics of Exercise Blood Pressure and Incident Hypertension.” JAMA Cardiology. doi:10.1001/jamacardio.2024.1397

About Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center is a leading academic medical center, where extraordinary care is supported by high-quality education and research. BIDMC is a teaching affiliate of Harvard Medical School, and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is the official hospital of the Boston Red Sox.

Beth Israel Deaconess Medical Center is a part of Beth Israel Lahey Health, a health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,700 physicians and 39,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.